The 9th RNA-Targeted Drug Discovery & Development Summit brings together the leaders advancing RNA-targeted small molecules from early discovery through clinical development. Join senior decision-makers, technical experts, and scientific innovators from biotech, pharma, and academia to uncover the latest advances in RNA-targeted therapeutics.

Large Pharma & Strategic Partners

For organizations evaluating RNA-targeted small molecules as the next therapeutic modality.

Key companies include: AstraZeneca, Sanofi, Pfizer, Novartis, Eli Lilly, Astellas, Chugai, Daiichi Sankyo.

Placeholder Image

Biotech Executives, Founders & CSOs

Join the executive leaders accelerating the next generation of RNA-targeted therapeutics and discover where the field is headed next.

Key companies include: Remix Therapeutics, PTC Therapeutics, ReviR Therapeutics, Sanofi, Pfizer, Ribonaut Therapeutics, Atomic AI, Dewpoint Therapeutics, EPICS Therapeutics, AstraZeneca, Ribometrix, Arrakis Therapeutics.

Biotech Drug Developers

For companies building RNA-targeted small molecule platforms and pipelines.

Key companies include: Remix Therapeutics, ReviR Therapeutics, Arrakis Therapeutics, Ribometrix, Ribonaut Therapeutics, Dewpoint Therapeutics, Syrna Therapeutics, Renasis Bio, RevoNA Bio.

Placeholder Image

Discovery & Translational Scientists

For technical experts developing the next generation of RNA-targeted therapeutics.

Key functions include: RNA Biology, Medicinal Chemistry, Drug Discovery, Screening, Structural Biology, Computational Biology, and Translational Sciences.

Placeholder Image

Academic & Research Pioneers

For researchers advancing understanding of RNA structure, biology and druggability.

Institutions include: UNC Chapel Hill, University of Toronto, University of Colorado Boulder, University of Wisconsin–Madison and many more.

Placeholder Image
Speakers Image
Explore the Agenda

Hear the latest industry advances in RNA target selection, structure-guided design, selective modulation and translational strategies across the full RNA-targeted small molecule pipeline and during our packed agenda, interactive roundtables, and panel discussions.

Networking Image (2) (1) (1) (1)
Partner With Us

Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.

4-1 (1)
Join Biopharma Experts

Connect with RNA-targeted small molecule leaders across discovery, preclinical and clinical development during our dedicated networking sessions to exchange insights, build collaborations and strengthen decisions from target selection to therapeutic impact.